![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » PFIZER'S ANTIFUNGAL DRUG APPROVED FOR NEW INDICATIONS
PFIZER'S ANTIFUNGAL DRUG APPROVED FOR NEW INDICATIONS
The FDA has approved Pfizer's Vfend as a treatment for deep-tissue skin infections, as well as infections in the abdomen, kidney, bladder wall and wounds. Vfend (voriconazole; IV for injection, tablets and oral suspension) also was cleared by the agency as a therapy for candidemia in patients without low white blood cell counts.
The drug already was approved in the U.S. to treat invasive aspergillosis and esophageal candidiasis and to serve as a salvage therapy for fungal infections caused by Scedosporium apiospermum and Fusarium species.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
11Jul
-
18Jul
-
21Oct